Pegasparaginase: where do we stand?

By Zeidan Amer   Wang Eunice S   Wetzler Meir  

Expert Opinion on Biological Therapy, Vol. 9, Iss. 1, 2009-01 ,pp. : 111-119

Informa Healthcare

Access to resources Recommend Favorite

Uterus transplantation: where do we stand today and where should we go?

By Brännström Mats   Wranning Caiza Almén  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 4, 2007-04 ,pp. : 427-429

Informa Healthcare

Access to resources Recommend Favorite

Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

By Lü Chen   Williams Andrew K   Chalasani Venu   Martínez Carlos H   Chin Joseph  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 1, 2011-01 ,pp. : 99-108

Informa Healthcare

Access to resources Recommend Favorite

Can we develop biomarkers that predict response of cancer patients to immunotherapy?

By Bonavida B.   Huerta-Yepez S.   Goodglick L.   Mizutani Y.   Miki T.  

Biomarkers, Vol. 10, Iss. 1, 2005-11 ,pp. : 69-76

Informa Healthcare

Access to resources Recommend Favorite

Perspectives on MAO-B in aging and neurological disease: Where do we go from here?

By Kumar M.   Andersen Julie  

Molecular Neurobiology, Vol. 30, Iss. 1, 2004-08 ,pp. : 77-89

Humana Press, Inc

Access to resources Recommend Favorite